NEW YORK (GenomeWeb) – Sequenom next month plans to launch in international markets a second noninvasive prenatal test, called VisibiliT, that targets women with average-risk pregnancies and has both lower cost and content than its existing MaterniT21 Plus test,. The firm will also further expand MaterniT21 Plus, which it offers for increased-risk pregnancies, to include three additional clinically relevant microdeletions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.